0001193125-26-182259.txt : 20260427 0001193125-26-182259.hdr.sgml : 20260427 20260427163941 ACCESSION NUMBER: 0001193125-26-182259 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260427 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Prout Samantha CENTRAL INDEX KEY: 0001743122 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 26901640 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER NAME: FORMER CONFORMED NAME: Prout Samantha Whiteman DATE OF NAME CHANGE: 20180607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0609 4 2026-04-27 true 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001743122 Prout Samantha false 47 HULFISH STREET PRINCETON NJ 08542 false true false false Chief Accounting Officer false Common Stock 2026-04-27 4 D false 125951 14.50 D 0 D Stock Options (right to buy) 9.55 2026-04-27 4 D false 2526 D 2030-01-02 Common Stock 2526 0 D Stock Options (right to buy) 10.03 2026-04-27 4 D false 3176 D 2030-04-15 Common Stock 3176 0 D Stock Options (right to buy) 12.11 2026-04-27 4 D false 37810 D 2032-01-14 Common Stock 37810 0 D Stock Options (right to buy) 11.93 2026-04-27 4 D false 55203 D 2033-01-03 Common Stock 55203 0 D Stock Options (right to buy) 14.24 2026-04-27 4 D false 43592 D 2034-01-02 Common Stock 43592 0 D Stock Options (right to buy) 9.41 2026-04-27 4 D false 62715 D 2035-01-03 Common Stock 62715 0 D The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 47,394 shares of Common Stock and 78,557 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger. /s/ Christian Formica, Attorney-in-Fact 2026-04-27